Erschienen in:
10.07.2018 | Editorial
Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
verfasst von:
Tatsuo Kanda, Shunichi Matsuoka, Mitsuhiko Moriyama
Erschienen in:
Hepatology International
|
Ausgabe 4/2018
Einloggen, um Zugang zu erhalten
Excerpt
In interferon-free treatment era, therapeutic regimens and sustained virological response (SVR) rates differ among different hepatitis C virus (HCV) genotypes (GTs) with either interferon-including or interferon-free treatments. The estimated rates of HCV infection in Egypt is around 14.7%, and the predominant HCV GT is GT4, where GT4a, GT4b, GT1 and GT3 represent 63, 30, 6 and 1% of cases, respectively [
1]. Recently, the results of treatment with combinations of direct-acting antivirals (DAAs) for HCV GT4 Egyptian patients have been reported [
2‐
6]. Almost all of these regimens could lead to more than 95% or more than 90% SVR rates, respectively, in the following patients: “easy-to-treat” patients who were treatment-naïve and did not have cirrhosis but had compensated liver biochemical parameters or “difficult-to-treat” patients who had previously failed interferon therapy with or without DAAs or an interferon-free combination, regardless of fibrosis stage, and had cirrhosis. …
